Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Aptinyx data reveal statistical trauma
An attempt to abrogate the placebo response does not seem to have gone as planned.
Medtech
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Post-Brexit device rules risk the UK falling behind
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Company Events
Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Interviews
The other kind of Covid-19 immunity
As antibody tests pile up, Oxford Immunotec is working on an assay to detect T-cell responses to the coronavirus.
Novo adds weight to its obesity goals
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
Healthineers’ Covid-19 antibody test spikes an interest in vaccines
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.